New therapies are reshaping geographic atrophy—but are trial endpoints keeping pace with clinical reality? Anat Loewenstein (Israel) is joined by Sobha Sivaprasad (UK) and Kristina Pfau (Switzerland) to examine how success in GA is measured, from lesion growth to functional vision. The panel explores microperimetry, contrast sensitivity, and emerging tools that may better reflect meaningful patient outcomes.
Members can continue the conversation in the EURETINA Forum.
Browse all podcast episodes here.
Listen on your preferred podcast player:
